ScholarLens Back to search
2012•World Clinical DrugsRequires access

Research progress of non-small cell lung cancer individualized chemotherapy

Wang Li

Open publisher page 0 citations

Abstract

Non-small cell lung cancer(NSCLC) is the malignant tumor with the highest incidence and mortality.The combination of the third generation of chemotherapy drugs(vinorelbine,gemcitabine,paclitaxel,docetaxel) with platinum-based drugs so far has been the common practice of NSCLC first-line treatment.New target genes related to chemotherapeutic effect(ERCC-1 and platinum-based resistance,RRM-1 and gemcitabine resistance,β-tubulin and paclitaxel resistance) are of the potential to be the biomarker of predicting chemotherapy reaction.This review describes integration of molecular pathological types and individualized chemotherapy.

About this research paper

What this paper is about

Non-small cell lung cancer(NSCLC) is the malignant tumor with the highest incidence and mortality.The combination of the third generation of chemotherapy drugs(vinorelbine,gemcitabine,paclitaxel,docetaxel) with platinum-based drugs so far has been the common practice of NSCLC first-line treatment.New target genes related to chemotherapeutic effect(ERCC-1 and platinum-based resistance,RRM-1 and gemcitabine resistance,β-tubulin and paclitaxel resistance) are of the potential to be the biomarker of predicting chemotherapy reaction.This review describes integration of molecular pathological types and individualized chemotherapy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Non-small cell lung cancer(NSCLC) is the malignant tumor with the highest incidence and mortality.The combination of the third generation of chemotherapy drugs(vinorelbine,gemcitabine,paclitaxel,docetaxel) with platinum-based drugs so far has been the common practice of NSCLC first-line treatment.New target genes related to chemotherapeutic effect(ERCC-1 and platinum-based resistance,RRM-1 and gemcitabine resistance,β-tubulin and paclitaxel resistance) are of the potential to be the biomarker of predicting chemotherapy reaction.This review describes integration of molecular pathological types and individualized chemotherapy.

Key concepts: Medicine, Vinorelbine, Docetaxel, Gemcitabine, Lung cancer, Paclitaxel, Chemotherapy, Oncology

Back to paper searchBrowse research topicsOriginal source
Research progress of non-small cell lung cancer individualized chemotherapy — Research Paper | ScholarLens